Myocardial heat shock protein 60 expression in insulin-resistant and diabetic rats.
Heat shock protein 60 (HSPD1) plays a critical role in myocardial protection. Its reduced expression may lower myocardial protection against ischemic injury in the diabetic state. This study was conducted to investigate the natural course of fructose-fed insulin-resistant rats, define changes in myocardial HSPD1 expression, and determine the effects of thiazolidinedione or anti-hypertensive treatment. Results showed that insulin resistance with hyperinsulinemia and hypertension developed after 6 weeks of fructose feeding. This time-course study also showed that myocardial HSPD1 expression was mildly increased in week 6 (P=0.05) and significantly increased in week 8. Rosiglitazone-treated rats had restored systolic blood pressure (BP) and normalized plasma insulin level during oral glucose tolerance tests, whereas amlodipine-treated rats restored only systolic BP. Both amlodipine and rosiglitazone treatments normalized the abundance of myocardial HSPD1 expression in fructose-fed rats. When these rats received streptozotocin injection and diabetes developed, myocardial HSPD1 expression decreased despite persistent hypertension. In conclusion, this is the first study to report that myocardial HSPD1 expression is increased in high-fructose-fed rats, which may be due to increased BP. Once the high-fructose-fed rats developed diabetes with insulin deficiency, the myocardial HSPD1 expression decreased in spite of persistent hypertension.
Chen
Harn-Shen
HS
Division of Endocrinology and Metabolism, Department of Medicine, Taipei Veterans General Hospital, No. 201, Shih-Pai Road, Sec 2, Taipei 11217, Taiwan, ROC. chenhs@vghtpe.gov.tw
Wu
Tzu-En
TE
Juan
Chi-Chang
CC
Lin
Hong-Da
HD
D017311:Amlodipine / Q000008:administration & dosage; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage; D018834:Chaperonin 60 / Q000235:genetics*; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000235:genetics*; D004195:Disease Models, Animal; D005632:Fructose / Q000008:administration & dosage; D015870:Gene Expression; D006946:Hyperinsulinism; D006973:Hypertension / Q000188:drug therapy; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007333:Insulin Resistance / Q000235:genetics; D008297:Male; D009206:Myocardium / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D000077154:Rosiglitazone; D013311:Streptozocin / Q000494:pharmacology; D045162:Thiazolidinediones / Q000494:pharmacology*
D000959:Antihypertensive Agents; D018834:Chaperonin 60; D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D017311:Amlodipine; D005632:Fructose; D013311:Streptozocin